Table 2 Study inclusion and exclusion criteria.

From: CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms

Inclusion criteria

Age ≥ 18 years

Date of first examination at the Department of Haematology between April 7, 2011 and September 13, 2016

Clinical and/or laboratory suspicion of MPN

Agreement to undergo genetic testing

Exclusion criteria

JAK2 V617F mutation confirmed by genetic testing

Inability to obtain an appropriate DNA sample from the available material at the blood sample library

Back to article page